HLX-42 is EGFR-targeting ADC with activity in several cancer models
Oct. 31, 2023
Researchers from Shanghai Henlius Biotech Inc. presented the discovery and preclinical characterization of HLX-42, a next-generation EGFR-targeting antibody-drug conjugate (ADC) being developed for the treatment of cancer.